Table 2.
Demographics, Comorbidity and risk factors among all PERT activations.
| All PERT activations |
Non-confirmed PE |
Confirmed PE |
||||
|---|---|---|---|---|---|---|
| n | %/SD | n | %/SD | n | %/SD | |
| PERT Activations | 475 | 100.0% | 59 | 12.4% | 416 | 87.6% |
| Demographics | ||||||
| Age in years (mean, SD) | 61.7 | 17.7 | 67.1 | 15.9 | 61.2* | 17.8 |
| Male | 231 | 48.6% | 24 | 40.7% | 207 | 49.8% |
| Race/ethnicity | ||||||
| Asian | 7 | 1.5% | 1 | 1.7% | 6 | 1.4% |
| Black or African American | 120 | 25.3% | 14 | 23.7% | 106 | 25.5% |
| Hispanic or Latino Ethnicity | 19 | 4.0% | 3 | 5.1% | 16 | 3.8% |
| White | 285 | 60.0% | 37 | 62.7% | 248 | 59.6% |
| Other/unknown | 42 | 8.8% | 3 | 5.1% | 39 | 9.4% |
| Height in cm (mean/SD) | 170.3 | 23.8 | 172.2 | 8.4 | 170.2 | 24.5 |
| Weight in kg (mean/SD) | 93.6 | 29.5 | 92.6 | 27.6 | 93.6 | 29.7 |
| Body mass index (mean/SD) | 31.9 | 10.0 | 31.1 | 8.4 | 31.9 | 10.1 |
| Primary insurance | ||||||
| None/self pay | 16 | 3.4% | 2 | 3.4% | 14 | 3.4% |
| Private insurance | 151 | 31.8% | 8 | 13.6% | 143 | 34.4% |
| Medicare | 171 | 36.0% | 10 | 16.9% | 161 | 38.7% |
| Medicaid | 44 | 9.3% | 3 | 5.1% | 41 | 9.9% |
| Military | 2 | 0.4% | 0 | 0% | 2 | 0.5% |
| Other | 7 | 1.5% | 0 | 0% | 7 | 1.7% |
| Unknown | 39 | 11.5% | 31 | 8.4% | 39 | 11.8% |
| Comorbid illness | ||||||
| Chronic obstructive pulmonary disease | 48 | 10.1% | 6 | 10.2% | 42 | 10.1% |
| Connective tissue disease | 11 | 2.3% | 1 | 1.7% | 10 | 2.4% |
| Congestive heart failure | 26 | 5.5% | 3 | 5.1% | 23 | 5.5% |
| Coronary heart disease | 66 | 13.9% | 6 | 10.2% | 60 | 14.4% |
| Depression/anxiety | 78 | 16.4% | 4 | 6.8% | 74 | 17.8% |
| Diabetes | 107 | 22.5% | 7 | 11.9% | 100 | 24.0% |
| Gastrointestinal bleeding | 13 | 2.7% | 1 | 1.7% | 12 | 2.9% |
| Hypertension | 255 | 53.7% | 13 | 22.0% | 242 | 58.2% |
| Malignancy | 118 | 24.8% | 7 | 11.9% | 111 | 26.7% |
| Hematologic | 10 | 2.1% | 1 | 1.7% | 9 | 2.2% |
| Solid | 106 | 22.3% | 6 | 10.2% | 100 | 24.0% |
| Known solid tumor metastases | 49 | 10.3% | 3 | 5.1% | 46 | 11.1% |
| Active treatment | 35 | 7.4% | 3 | 5.1% | 32 | 7.7% |
| Renal insufficiency/failure | 39 | 8.2% | 3 | 5.1% | 36 | 8.7% |
| Stroke/neurovascular disease | 30 | 6.3% | 2 | 3.4% | 28 | 6.7% |
| Charlson comorbidity index (mean SD) | 1.9 | 2.4 | 1.0 | 2.0 | 2.0* | 2.4 |
| Other PE Risk Factors | ||||||
| Smoking | 141 | 29.7% | 13 | 22.0% | 128 | 30.8% |
| Recent hospitalization | 102 | 21.5% | 5 | 8.5% | 97 | 23.3% |
| Reduced mobility | 69 | 14.5% | 4 | 6.8% | 65 | 15.6% |
| Recent surgery or invasive procedure | 88 | 18.5% | 4 | 6.8% | 84 | 20.2% |
| Prior PE | 69 | 14.5% | 2 | 3.4% | 67 | 16.1% |
| Prior DVT | 75 | 15.8% | 3 | 5.1% | 72 | 17.3% |
| Family history of VTE | 30 | 6.3% | 0 | 0% | 30 | 7.2% |
| Hormone use | 29 | 6.1% | 1 | 1.7% | 28 | 6.7% |
| Recent trauma | 22 | 4.6% | 3 | 5.1% | 19 | 4.6% |
| Indwelling catheter | 17 | 3.6% | 0 | 0% | 17 | 4.1% |
Demographics, comorbidity, and risk factors among all PERT activations presented for all activations, confirmed PE and non-confirmed PE. SD: Standard deviation. *P < 0.05 (confirmed vs. non-confirmed).